Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection-United States, 2012-2016

Clin Infect Dis. 2020 Dec 3;71(9):2502-2505. doi: 10.1093/cid/ciaa286.

Abstract

We analyzed data from 2012 to 2016 for patients who were hospitalized or who died after ≥1 dose of isoniazid-rifapentine for treatment of latent Mycobacterium tuberculosis infection. No patients died; 15 were hospitalized. Nine patients experienced hypotension, and 5 had elevated serum aminotransferases, reinforcing the need for vigilant monitoring during treatment.

Keywords: adverse; isoniazid; latent; rifapentine; tuberculosis.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antitubercular Agents / adverse effects
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Humans
  • Isoniazid / adverse effects
  • Latent Tuberculosis* / drug therapy
  • Mycobacterium tuberculosis*
  • Rifampin / adverse effects
  • Rifampin / analogs & derivatives
  • United States / epidemiology

Substances

  • Antitubercular Agents
  • Isoniazid
  • Rifampin
  • rifapentine